Literature DB >> 26146419

Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives.

Mike A Richardson1, Robert E Furlani2, Brendan K Podell1, David F Ackart1, Jessica D Haugen1, Roberta J Melander2, Christian Melander2, Randall J Basaraba1.   

Abstract

Advanced glycation end-products (AGEs), unregulated modifications to host macromolecules that occur as a result of metabolic dysregulation, play a role in many diabetes related complications, inflammation and aging, and may lead to increased cardiovascular risk. Small molecules that have the ability to inhibit AGE formation, and even break preformed AGEs have enormous therapeutic potential in the treatment of these disease states. We report the screening of a series of 2-aminoimidazloles for anti-AGE activity, and the identification of a bis-2-aminoimidazole lead compound that possesses superior AGE inhibition and breaking activity compared to the known AGE inhibitor aminoguanidine.

Entities:  

Keywords:  Advanced glycation end-products (AGEs); Aminoguanidine; Bis-2-aminoimidazole; Diabetes

Year:  2015        PMID： 26146419      PMCID： PMC4487526          DOI： 10.1016/j.tetlet.2015.01.122

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN： 0040-4039            Impact factor:   2.415


  22 in total

1.  Evaluation of the toxicity of 2-aminoimidazole antibiofilm agents using both cellular and model organism systems.

Authors:  Sean D Stowe; Ashley T Tucker; Richele Thompson; Amanda Piper; Justin J Richards; Steven A Rogers; Laura D Mathies; Christian Melander; John Cavanagh
Journal:  Drug Chem Toxicol       Date:  2012-01-31       Impact factor: 3.356

2.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

Review 3.  Current therapeutic interventions in the glycation pathway: evidence from clinical studies.

Authors:  L Engelen; C D A Stehouwer; C G Schalkwijk
Journal:  Diabetes Obes Metab       Date:  2013-01-25       Impact factor: 6.577

Review 4.  Advanced glycation end products: sparking the development of diabetic vascular injury.

Authors:  Alison Goldin; Joshua A Beckman; Ann Marie Schmidt; Mark A Creager
Journal:  Circulation       Date:  2006-08-08       Impact factor: 29.690

5.  Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.

Authors:  Jasper W L Hartog; Suzan Willemsen; Dirk J van Veldhuisen; Jan L Posma; Leen M van Wijk; Yoran M Hummel; Hans L Hillege; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2011-06-13       Impact factor: 15.534

Review 6.  Baking, ageing, diabetes: a short history of the Maillard reaction.

Authors:  Michael Hellwig; Thomas Henle
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-09       Impact factor: 15.336

Review 7.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

8.  Amide isosteres of oroidin: assessment of antibiofilm activity and C. elegans toxicity.

Authors:  Justin J Richards; Samuel Reyes; Sean D Stowe; Ashley T Tucker; T Eric Ballard; Laura D Mathies; John Cavanagh; Christian Melander
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

9.  The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.

Authors:  Robert W Huigens; Samuel Reyes; Catherine S Reed; Cynthia Bunders; Steven A Rogers; Andrew T Steinhauer; Christian Melander
Journal:  Bioorg Med Chem       Date:  2009-12-06       Impact factor: 3.641

10.  Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.

Authors:  Suzan Willemsen; Jasper W L Hartog; Yoran M Hummel; Jan L Posma; Leen M van Wijk; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2010-01-25       Impact factor: 15.534
View more
  5 in total

1.  Second generation 2-aminoimidazole based advanced glycation end product inhibitors and breakers.

Authors:  Robert E Furlani; Mike A Richardson; Brendan K Podell; David F Ackart; Jessica D Haugen; Roberta J Melander; Randall J Basaraba; Christian Melander
Journal:  Bioorg Med Chem Lett       Date:  2015-06-29       Impact factor: 2.823

2.  Aminoguanidine reduces diabetes-associated cardiac fibrosis.

Authors:  Fernando Magdaleno; Chuck Christopher Blajszczak; Claudia Lisette Charles-Niño; Alma Marlene Guadrón-Llanos; Alan Omar Vázquez-Álvarez; Alejandra Guillermina Miranda-Díaz; Natalia Nieto; María Cristina Islas-Carbajal; Ana Rosa Rincón-Sánchez
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

Review 3.  Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms.

Authors:  Katharina Ronacher; Reinout van Crevel; Julia A Critchley; Andrew A Bremer; Larry S Schlesinger; Anil Kapur; Randall Basaraba; Hardy Kornfeld; Blanca I Restrepo
Journal:  Chest       Date:  2017-04-20       Impact factor: 9.410

Review 4.  Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Authors:  Dilara Kiran; Brendan K Podell; Mark Chambers; Randall J Basaraba
Journal:  Semin Immunopathol       Date:  2015-10-28       Impact factor: 9.623

5.  Advanced glycation end products and their receptors in serum of patients with type 2 diabetes.

Authors:  Diana Indyk; Agnieszka Bronowicka-Szydełko; Andrzej Gamian; Aleksandra Kuzan
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.